Experienced in Pericarditis

Marc Fila

CHU Robert Debré
Paris, FR 
Experienced in Pericarditis
CHU Robert Debré
Paris, FR 
OverviewLocationsClinical Research

Overview

Marc Fila practices in Paris, France. Mr. Fila is rated as an Experienced expert by MediFind in the treatment of Pericarditis. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Nephrocalcinosis, and Kidney Transplant.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pericarditis.

Gender
Male

Locations

CHU Robert Debré
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
Enrollment Status: Terminated
Publish Date: September 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: July 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

86 Total Publications

Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome.
Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome.
Journal: Kidney international reports
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fila's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile